Aligos therapeutics announces $105 million private placement financing

Proceeds expected to fund the start of the alg-000184 phase 2 clinical study funding expected to extend cash runway into the second half of 2026 south san francisco, calif., feb. 12, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”, “company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses.
ALGS Ratings Summary
ALGS Quant Ranking